With the use of immunoblotting marked with antibody against MUC5AC, Wongkham et al. detected this type of mucin in ~62% of CC patients, as compared with only 3% of patients with benign hepatobiliary diseases, 10% with hepato-gastrointestinal cancer and none of the healthy control. The gene discussed is MUC5AC; the disease is cholangiocarcinoma.